In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with metastatic grade 1/2 (Ki-67 ≤ 10%) non-functioning NET and documented baseline tumour-progression status received lanreotide Autogel 120 mg (n = 101) or placebo (n = 103) for 96 weeks or until death/progressive disease (PD) in CLARINET study. Patients with stable disease (SD) at core study end (lanreotide/placebo) or PD (placebo only) continued or switched to lanreotide in the OLE. In total, 88 patients (previously: lanreotide, n = 41; placebo, n = 47) participated: 38% had pancreatic, 39% midgut and 23% other/unknown primary tumours. Patients continuing lanreotide reported fewer adverse events (AEs) (all and treatment-related) during OLE than core study. Placebo-to-lanreotide switch patients reported similar AE rates in OLE and core studies, except more diarrhoea was considered treatment-related in OLE (overall diarrhoea unchanged). Median lanreotide PFS (core study randomisation to PD in core/OLE; n=101) was 32.8 months (95% CI: 30.9, 68.0). A sensitivity analysis, addressing potential selection bias by assuming that patients with SD on lanreotide in the core study and not entering the OLE (n=13) had PD 24 weeks after last core assessment, found median PFS remaining consistent: 30.8 months (95% CI: 30.0, 31.3). Median time to further PD after placebo-to-lanreotide switch (n=32) was 14.0 months (10.1; not reached). This OLE study suggests long-term treatment with lanreotide Autogel 120 mg maintained favourable safety/tolerability. CLARINET OLE data also provide new evidence of lanreotide anti-tumour benefits in indolent and progressive pancreatic/intestinal NETs.

Royal Free HospitalLondon UKCharité University Medicine BerlinBerlin GermanyUniversity of Warmia and MazuryOlsztyn PolandUniversity of Texas MD Anderson Cancer CenterHouston Texas USAUniversity HospitalVienna AustriaDepartment of Oncology of the 1st Faculty of Medicine and General Teaching HospitalPrague Czech RepublicRobert Debré HospitalReims FranceMarkey Cancer CenterUniversity of Kentucky Lexington Kentucky USAVall d'Hebron University HospitalBarcelona SpainWestern General HospitalEdinburgh UKUniversità Cattolica del Sacro CuoreRome ItalyIpsenLes Ulis FranceIpsenBasking Ridge New Jersey USABeaujon HospitalClichy FranceParis Diderot UniversityParis France

Royal Free HospitalLondon UKCharité University Medicine BerlinBerlin GermanyUniversity of Warmia and MazuryOlsztyn PolandUniversity of Texas MD Anderson Cancer CenterHouston Texas USAUniversity HospitalVienna AustriaDepartment of Oncology of the 1st Faculty of Medicine and General Teaching HospitalPrague Czech RepublicRobert Debré HospitalReims FranceMarkey Cancer CenterUniversity of Kentucky Lexington Kentucky USAVall d'Hebron University HospitalBarcelona SpainWestern General HospitalEdinburgh UKUniversità Cattolica del Sacro CuoreRome ItalyIpsenLes Ulis FranceIpsenBasking Ridge New Jersey USABeaujon HospitalClichy FranceParis Diderot UniversityParis France Royal Free HospitalLondon UKCharité University Medicine BerlinBerlin GermanyUniversity of Warmia and MazuryOlsztyn PolandUniversity of Texas MD Anderson Cancer CenterHouston Texas USAUniversity HospitalVienna AustriaDepartment of Oncology of the 1st Faculty of Medicine and General Teaching HospitalPrague Czech RepublicRobert Debré HospitalReims FranceMarkey Cancer CenterUniversity of Kentucky Lexington Kentucky USAVall d'Hebron University HospitalBarcelona SpainWestern General HospitalEdinburgh UKUniversità Cattolica del Sacro CuoreRome ItalyIpsenLes Ulis FranceIpsenBasking Ridge New Jersey USABeaujon HospitalClichy FranceParis Diderot UniversityParis France

Zobrazit více v PubMed

Bajetta E, Procopio G, Catena L, Martinetti A, De DS, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer. 2006;107:2474–2481. doi: 10.1002/cncr.22272. PubMed DOI

Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine. 2014;371:224–233. doi: 10.1056/NEJMoa1316158. PubMed DOI

Food and Drug Administration (FDA) 2007 Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD, USA: U.S. Department of Health and Human Services, Food and Drug Administration. (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf)

Ipsen Biopharmaceuticals, Inc. 2014 SOMATULINE DEPOT labeling revision 12/22/2014 Reference ID: 3677425. Basking Ridge, NJ, USA: Ipsen Biopharmaceuticals, Inc. (available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s010lbl.pdf)

Ipsen Ltd. 2015 Somatuline® Autogel®. Summary of product characteristics (SmPC). Slough, Berkshire, UK: Ipsen Ltd. (available at: http://www.medicines.org.uk/emc/medicine/25104)

Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) Alimentary Pharmacology & Therapeutics. 2011;34:235–242. doi: 10.1111/j.1365-2036.2011.04693.x. PubMed DOI

Martin-Richard M, Massuti B, Pineda E, Alonso V, Marmol M, Castellano D, Castellano D, Fonseca E, Galán A, Llanos M, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013;13:427. doi: 10.1186/1471-2407-13-427. PubMed DOI PMC

National Comprehensive Cancer Network (NCCN) 2014 NCCN clinical practice guidelines in oncology: Neuroendocrine tumors. Version 1. Fort Washington, PA, USA: National Comprehensive Cancer Network. (available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp) PubMed

Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V, Vullierme MP, Couvelard A, Hentic O, Ruszniewski P. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. European Journal of Gastroenterology & Hepatology. 2013;25:232–238. doi: 10.1097/MEG.0b013e328359d1a6. PubMed DOI

Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape U-F, et al. Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology [in press] 2016 doi: 10.1159/000443167. PubMed DOI

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine. 2012;364:501–513. doi: 10.1056/NEJMoa1003825. PubMed DOI

Rinke A 2012 Benefit of octreotide LAR in patients with neuroendocrine midgut tumors who previously progressed on placebo therapy: two cases from the PROMID study. [abstract C117]. Presented at 9th Annual ENETS Conference, 7–9 March 2012, Copenhagen, Denmark.

Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80:244–251. doi: 10.1159/000082875. PubMed DOI

Yao JC, Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine. 2011;364:514–523. doi: 10.1056/NEJMoa1009290. PubMed DOI PMC

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study